UBS Group
AKBA icon

UBS Group’s Akebia Therapeutics AKBA Stock Holding History

UBS Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,000
Closed -$8.34K – 10414
2026
Q1 		$8.34K Buy
+6,000
New +$8.25K ﹤0.01% 8515

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's AKBA Position: Q2 2026 in Review

UBS Group increased its Akebia Therapeutics (AKBA) stake by 79% in Q2 2026, buying an estimated $721K and bringing the position to 1,374,950 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #5330.

UBS Group first reported a position in AKBA in Q4 2014 and has held it in 47 quarters since. The position peaked at $9.95M in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • UBS Group held 1,374,950 shares of Akebia Therapeutics worth $1.57M as of Q2 2026.
  • UBS Group bought 605,479 Akebia Therapeutics shares in Q2 2026, an estimated $721K.
  • Akebia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5330 holding.
  • UBS Group first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Akebia Therapeutics position peaked at $9.95M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.